

# BOSPHORUS MYELOMA FORUM 2026

Treatment Sequencing in the Era of  
Cellular and Immune Therapies

June 6, 2026 The Ritz-Carlton Hotel, Istanbul

09:15 – 09:30 **Welcome & Opening Remarks**  
Dr. Tayfur TOPTAŞ & Dr. Yıldız İPEK

09:30 – 10:30 **SESSION I – OPTIMIZING FRONTLINE STRATEGY**  
Chairs: Dr. Şehmus ERTOP, Dr. Şebnem İZMİR GÜNER

09:30 – 09:55 Smoldering Myeloma in 2026: Who Should We Treat and How Early?  
**Speaker:** Dr. Yıldız İPEK  
*Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey*

09:55 – 10:00 Discussion

10:00 – 10:25 Frontline Myeloma in 2026: Quadruplets, Transplant and the First Sequencing Decision  
**Speaker:** Dr. Ayşe SALİHOĞLU  
*Istanbul University, Istanbul, Turkey*

10:25 – 10:30 Discussion

10:30 – 10:45 **COFFEE BREAK**



10:45 – 11:45 **SESSION II – CELLULAR AND IMMUNE THERAPIES**  
Chairs: Dr. Figen ATALAY, Dr. Erman ÖZTÜRK

10:45 – 11:10 Positioning CAR-T in Relapsed Myeloma: Patient Selection,  
Timing and Toxicity Management in 2026  
**Speaker:** Dr. Vladan VUCINIC  
*University of Leipzig, Leipzig, Germany*

11:10 – 11:15 Discussion

11:15 – 11:40 Bispecific Antibodies in 2026: Sequencing, Safety and Practical Integration  
**Speaker:** Dr. Ömür Gökmen SEVİNDİK  
*Florence Nightingale Hospital, Istanbul, Turkey*

11:40 – 11:45 Discussion

12:00 – 13:30 **LUNCH BREAK**



13:30 – 14:45 **SESSION III – RELAPSE STRATEGY MRD-ADAPTED DECISIONS**  
Chairs: Dr. Tülin TUĞLULAR, Dr. Sinem CİVRİZ BOZDAĞ

13:30 – 13:55 Strategic Treatment Sequencing in Relapsed Multiple Myeloma:  
A 2026 Algorithmic Approach  
**Speaker:** Dr. Philippe MOREAU  
*University Hospital of Nantes, Nantes, France*

13:55 – 14:00 Discussion

14:00 – 14:25 Prevention and Treatment of Venous Thromboembolism in Patients with Multiple Myeloma  
**Speaker:** Dr. Grigorios GEROTZIAS  
*Sorbonne University, Paris, France*

14:25 – 14:30 Discussion

14:30 – 14:45 **COFFEE BREAK**



14:45 – 16:45 **SESSION IV – CHALLENGING DISEASE BIOLOGY**  
Chair: Dr. Zafer GÜLBAŞ, Dr. Tayfur TOPTAŞ

14:45 – 15:10 Sequencing Beyond CD38 and BCMA:  
The Role of XPO1 Inhibition and Other Novel Agents  
**Speaker:** Dr. Claudio CERCHIONE  
*Dino Amadori Romagna Institute for Cancer Research and Treatment (IRST) IRCCS, Meldola, Italy*

15:10 – 15:15 Discussion

15:15 – 15:40 Extramedullary Multiple Myeloma: Biology, Prognosis and Treatment Strategy  
**Speaker:** Dr. Meral BEKSAÇ  
*Liv Hospital Ankara, Ankara, Turkey*

15:40 – 16:45 Discussion

**Panelists:** Dr. Ahmet Mert YANIK, Dr. Ali Hakan KAYA, Dr. Ant UZAY, Dr. Arda BAYAR  
Dr. Ayşe Nilgün KUL, Dr. Ceren UZUNOĞLU, Dr. Damla ORTABOZ, Dr. Demet ÇEKDEMİR,  
Dr. Deram BÜYÜKTAŞ, Dr. Dilek ÖZDEN ÖZLÜK, Dr. Elif SAKCI, Dr. Emrah KILIÇASLAN,  
Dr. Eren ARSLAN DAVULCU, Dr. Fatma ARIKAN, Dr. Fatma TEMİZ,  
Dr. Fazıl Çağrı HUNUTLU, Dr. Gülkan ÖZKAN, Dr. Güven YILMAZ, Dr. Hakan KESKİ,  
Dr. Hasan Sami GÖKSOY, Dr. Işıl ERDOĞAN ÖZÜNAL, Dr. Leylagül KAYNAR,  
Dr. Osman KARA, Dr. Öykü ARSLAN, Dr. Özlem CANDAN, Dr. Tayfun ELİBOL,  
Dr. Toluy ÖZGÜMÜŞ, Dr. Tuğba GÜLLÜ KOCA

16:45 – 17:00 **Closing Remarks**  
Dr. Tayfur TOPTAŞ & Dr. Yıldız İPEK